British Business Bank’s Zinc Fund Will Mint 80 Startups

The British Business Bank will put up to £46 million into Zinc’s new Science-for-Impact Fund, a £70 million pot aimed at 80 UK deep tech startups. The cheque, agreed on 2 September 2026 through the Enterprise Capital Funds programme, is public money for the earliest stage of company creation, not for the later rounds where UK deep tech still struggles.

Eighty Companies Will Share a £70 Million Pot

Zinc Capital Management is targeting a £70 million Science-for-Impact Fund and says it will build a portfolio of 80 new deep tech companies in health and the environment. Split evenly, that is £875,000 of fund capital per company before fees, reserves and follow-on holdings, which is company-creation money rather than a scale-up round.

Dealroom logged UK deep tech funding at $11.3 billion in the first eight months of 2026, with deep tech making up 41% of European venture funding. The Bank is not starving that market of seed cheques. It is paying Zinc to turn scientists into companies before most venture firms will take a meeting.

ZINC II VERSUS THE NEW FUND

The new vehicle is just over twice the size of Zinc II’s £33 million target and plans 20 fewer companies, so fund capital per company rises 2.65 times on those targets. Ella Goldner, Zinc’s co-founder and managing partner, is still selling the same conversion problem she named when the firm started in 2017: British labs produce the science, then too few of those discoveries become companies.

Public Capital Covers Two Thirds of Zinc’s Raise

The £46 million sits just under the Enterprise Capital Funds ceiling of £50 million per fund, and it is 65.7% of Zinc’s £70 million target, which matches the programme rule that the Bank may provide up to two thirds of the money. Private investors only need to bring the remaining third, about £24 million if the fund hits its target, and they receive a better profit share than the Bank when a fund works.

Mark Sims, the Bank’s managing director for development equity funds, put the official case in the announcement.

Breakthrough businesses need support from the very earliest stages if they’re to realise their potential. Zinc has a strong track record of backing founders tackling significant health and environmental challenges, and we’re pleased to support the next phase of its growth. Our commitment to Zinc will help strengthen the pipeline of innovative businesses driving the UK’s future economy.

Mark Sims, Managing Director, Head of Development Equity Funds, British Business Bank

Dealroom counts this as the 55th fund backed under the ECF programme and notes that the Bank recently committed £50 million to Longwall Venture Partners’ £100 million deep tech fund and £25 million to Antler’s UK Fund II. The Zinc cheque is a regular tool, not a one-off rescue.

WHAT THE ECF RULES ALLOW ZINC TO DO

• Public share: The Bank can supply up to two thirds of an ECF and no more than £50 million in any single fund.
• Private sweetener: After capital is repaid, the Bank takes a reduced profit share so private investors keep more of the upside.
• Clock on the close: Managers must hit a first close with the agreed private money within six months of the award, or the Bank can walk away.
• First-round cap: An ECF cannot go into a company whose round, or any earlier round, exceeds £5 million.
• Follow-on cap: After twelve months, follow-on in one company cannot exceed the lower of 15% of fund size or £15 million, which on a £70 million fund is £10.5 million.

Those caps lock the Science-for-Impact Fund into the equity gap the programme was built for. Zinc can help a company get started and protect a stake in a later round. It cannot, under these rules, write the large growth cheque a therapeutics or hardware firm will eventually need.

What Zinc Puts Into a New Company

Zinc is a venture builder as much as a fund. Founders often arrive pre-team and pre-idea, join a cohort, and leave with a UK company, a first cheque and coaching. The firm’s current pre-seed page offers an initial investment of up to £250k, plus help on talent, intellectual property, customers and grants.

At that cheque size, 80 companies would absorb £20 million in first tickets if every one received the full £250,000, leaving the rest of a £70 million fund for fees, follow-on and the ones that get further than the first round. The model is volume with a modest first ticket, then selection.

Goldner described the bet in the Bank’s announcement, and it is a creation bet, not a scale-up bet.

The UK is home to some of the world’s most extraordinary scientific talent, yet too many breakthrough discoveries never become the companies that improve lives, protect our planet and create long-term economic value. We founded Zinc to change that by partnering with exceptional scientists and entrepreneurs across the UK at the earliest stages, helping transform world-class research into ventures that deliver lasting impact in health and the environment while building the globally significant businesses of the future.

Ella Goldner, Co-founder and Managing Partner, Zinc

A Zinc 2025 Science-for-Impact report put the existing book at 38 ventures, with three quarters of them coming through a venture-building programme rather than a cold pitch. The new fund is that machine with more capital per company than Zinc II, still pointed at the moment before a Series A.

Heart Drugs, Battery Scrap and a Blood Test

The science-for-impact ventures already in the portfolio show what the 80 new names are meant to look like. They are lab-heavy, slow to revenue, and still early.

FIVE ZINC COMPANIES THE NEW FUND IS BUILT TO RESEMBLE

Chris Watson spent 15 years at Queen’s University Belfast studying gene regulation in failing hearts before SignaCor, which is aimed at hypertrophic cardiomyopathy, a condition that affects one in 500 people in the UK. SignaCor won Zinc’s Discovery Spark cardiovascular group in March 2026. “There are very limited treatment options for these patients today,” Watson said.

Natalie Pankova, Zinc’s health and life science partner, said the firm backed SignaCor for the science plus a path to the clinic, and Darach Neeson, SignaCor’s chief executive, said the cash was meant to support Phase 2a trial plans. CellMine, led by Simon Rathbone and Adam Taylor out of Edinburgh’s Impact Solutions, is trying to turn mixed battery scrap into chemical products that can go back into the supply chain. Speek, co-founded by Kanu Batra, is a clinical product, not a gadget, for families dealing with teenage self-injury.

None of those businesses is a software app that can live on a £250,000 seed and a laptop. A heart drug, a battery plant and a regulated care product will need later rounds that the ECF first-round cap of £5 million cannot cover on its own.

Zinc’s Last Fund Tried to Create 100 Ventures

The Bank has been here with Zinc before. On 31 May 2022 the firm announced the first close of a £28 million fund, Zinc II, targeting a final close of £33 million. That fund was designed to back 500 entrepreneurs across seven venture-builder programmes and invest in 100 of the companies they created.

HOW ZINC AND THE BANK GOT HERE

1. 2017: Ella Goldner, Paul Kirby and Saul Klein found Zinc, with early backing that included the London School of Economics.
2. 31 May 2022: Zinc II records a £28 million first close, targeting £33 million, 500 entrepreneurs and 100 companies, with the Bank as ECF cornerstone.
3. 2 December 2024: Zinc leads the pre-seed round into CellMine, a lithium-ion battery recycling spin-out in Edinburgh.
4. March 2026: SignaCor joins the portfolio with £250,000 from Zinc after winning Discovery Spark.
5. 2 September 2026: The Bank agrees to commit up to £46 million to the Science-for-Impact Fund.

Zinc II’s missions were mental health, the natural environment, later life, and work under automation. The new fund narrows the brief to health and environment and to the government’s Industrial Strategy headings: advanced manufacturing, clean energy, life sciences, engineering, biology and AI. Fewer companies, more money per name, same public cornerstone.

Older Zinc names show the range of outcomes this method produces. Vira Health, the menopause company, raised about $14 million. Parla, a femtech firm, was bought by Holland & Barrett in 2022. Those are useful proofs of life. They are not a map for 80 deep tech firms through Series B.

The Late-Stage Gap Those 80 Firms Will Hit

The Royal Academy of Engineering’s Enterprise Hub, in its State of UK Deep Tech assessment published on 24 November 2025, found that UK domestic participation falls under 10 percent at late stage after standing at 57% at seed. Closing that gap, the Hub said, would take an extra $4 billion to $11 billion a year.

WHERE UK DEEP TECH STILL RUNS SHORT

• Seed versus late: UK investors are in 57% of seed and under 10% of late-stage rounds.
• The dollar gap: The Hub’s range for the missing late-stage capital is $4 billion to $11 billion a year.
• Who writes the late cheques: Most of that late money comes from the United States, with more from Germany, France, Japan and the Nordics.
• Where the early money sits: Sir John Lazar, then president of the Academy, said London, Cambridge and Oxford still took 77% of UK deep tech venture funding.

Ana Avaliani, director of the Enterprise Hub, said growth is held back by access to late-stage funding and that patient capital still has to match the time deep tech takes. Lord Vallance, then science minister, said the same report showed deep tech pulling money into life sciences and advanced manufacturing, and that the country still had to support scaling.

Academic spin-outs are the spine of that market. The Hub counted just under 1,000 VC-backed deep tech spin-outs since 2010, 34% of the UK deep tech set, and said the UK is better than the rest of Europe at getting firms from seed to Series A. The break comes after that. US firms are nearly twice as likely to reach Series C and three times as likely to reach Series D, in the Hub’s figures, and the UK’s conversion to unicorn status or $1 billion exits is less than half the US rate.

A Direct Equity Push Running in Parallel

The Bank already knows that later gap, because it has been writing those cheques itself. In June 2026 it said it had put more than £600 million into UK science and technology scale-ups and taken its direct equity book past 50 companies. Direct investing in the prior nine months had exceeded the previous four years.

In FY25/26 the Bank completed 18 new direct deals and 18 follow-ons, against 12 investments the year before, and moved that book from £75 million to £188 million, with a stated aim of more than £400 million in the following year. Charlotte Lawrence, managing director and head of direct equity, said the Bank was aiming to put £400 million a year into venture-backed UK scale-ups. Typical first cheques on that side run from £10 million to £40 million, with a plan for 14 to 18 new investments a year and cumulative holdings of up to £75 million in a single company.

That is a different machine from Zinc’s. Fourteen to 18 scale-up investments a year cannot absorb 80 new pre-seed science companies, and they are not meant to. The ECF arm pays for births. The direct equity arm pays for a much smaller set of survivors. In between sits the market the Hub measured, where UK institutions drop out and US funds, or a trade buyer, decide who stays British.

Zinc now has a public cornerstone large enough to run that birth process at 80 names and at £875,000 of fund capital per company on the headline maths. The companies that work will still need a later cheque the Science-for-Impact Fund is not allowed to write.

Disclaimer: This article is news reporting on a public-bank fund commitment and related venture figures, and it is for information only. It is not investment advice, a solicitation to commit capital to Zinc, the Science-for-Impact Fund or any portfolio company, and it is not a rating of those vehicles. Readers considering an allocation to venture funds or unlisted shares should consult a qualified financial adviser authorised for that work. Figures and fund statuses reflect the British Business Bank, Zinc, Dealroom and Royal Academy of Engineering materials cited above as of 2 September 2026 and may change as the fund closes and invests.